Abstract
Background: In Fabry cardiomyopathy, little is known about the interaction between its key feature of myocardial replacement fibrosis and changes in resting, Holter, and exercise electrocardiography (−ECG).
Methods and Results: Resting ECG, 24-h Holter ECG, and exercise ECG were performed in 95 patients (50 women) with Fabry disease, staged using cardiac magnetic resonance imaging to measure left ventricular fibrosis. With resting ECG, T alterations were seen in patients with cardiac fibrosis, while time intervals and rhythm were unchanged (except for a longer QRS duration in patients with severe fibrosis). All patients with severe fibrosis showed T inversion, ST alteration, or both. With Holter ECG, maximum and minimum heart rate did not differ with fibrosis severity. Patients without fibrotic tissue showed less ventricular premature beats (VPB) (median 5/24 h) compared to those with mild (median 11/24 h) or severe fibrosis (median 115/24 h; P < 0.05, respectively). Fibrosis was a strong predictor of VPB burden (r 2 = 0.5; P < 0.001). During exercise, patients with severe fibrosis had the least increase in systolic blood pressure (sBP) (47 ± 22 mmHg vs. 62 ± 25 mmHg, P < 0.05) and the lowest maximum heart rate (113 ± 18/min; P < 0.05). Patients with mild fibrosis had a high sBP during exercise (198 ± 37 mmHg; P < 0.05). Decreased diastolic blood pressure (>10 mmHg) occurred in some patients with no (3/41) or mild fibrosis (3/34) but not in patients with severe fibrosis (0/20; P < 0.01).
Conclusions: Our data suggest that cardiac replacement fibrosis is responsible for repolarization abnormalities on resting ECG and increased VPB with Holter ECG. During exercise ECG, advanced cardiomyopathy is characterized by chronotropic incompetence with limitations on blood pressure and heart rate increase.
Competing interests: None declared
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bouwman MG, Rombach SM, Schenk E, Sweeb A, Wijburg FA, Hollak CE, Linthorst GE (2012) Prevalence of symptoms in female Fabry disease patients: a case–control survey. J Inherit Metab Dis 35:891–898
Breunig F, Weidemann F, Beer M et al (2003) Fabry disease: diagnosis and treatment. Kidney Int Suppl 84:181–185
Kampmann C, Wiethoff CM, Martin C et al (2002) Electrocardiographic signs of hypertrophy in Fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 439:21–27
Koskenvuo JW, Kantola IM, Nuutila P et al (2010) Cardiopulmonary involvement in Fabry’s disease. Acta Cardiol 65:185–192
Krämer J, Niemann M, Störk S et al (2014) The burden of cardiac fibrosis determines malignant ventricular arrhythmias and outcome in Fabry disease. Am J Cardiol 114:895–900
Linhart A, Palecek T, Bultas J (2000) New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 139:101–108
Linhart A, Lubanda JC, Palecek T et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24:75–83
Lobo T, Morgan J, Bjorksten A, Nicholls K, Grigg L, Centra E, Becker G (2008) Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 38:407–414
Moon JC, Sachdev B, Elkington AG et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151–2155
Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson–Fabry disease. J Cardiovasc Magn Reson 8:479–482
Namdar M, Kampmann C, Steffel J et al (2010) PQ interval in patients with Fabry disease. Am J Cardiol 105:753–756
Namdar M, Steffel J, Vidovic M et al (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 97:485–490
Niemann M, Hartmann T, Namdar M et al (2013) Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease. J Inherit Metab Dis 36:873–879
Ramaswami U, Whybra C, Parini R et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92
Roudebush CP, Foerster JM, Bing OH (1973) The abbreviated PR interval of Fabry’s disease. N Eng J Med 16:357–358
Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson–Fabry disease. Am J Cardiol 96:842–846
Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227
Weidemann F, Linhart A, Monserrat L, Strotmann J (2010) Cardiac challenges in patients with Fabry disease. Int J Cardiol 14:3–10
Zarate Y, Hopkin R (2008) Fabry’s disease. Lancet 372:1427–1435
Acknowledgments
This work was supported by grants from the Bundesministerium für Bildung und Forschung (BMBF project 01EO1004), Germany.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Markus Ries, MD, PhD, MHSc, FCP
Appendices
Take-Home
Cardiac replacement fibrosis is responsible for clinical relevant electrical changes and seems to influence exercise intolerance in patients with Fabry disease.
Compliance with Ethics Guidelines
The authors state that the article has not been and will not be published elsewhere in substantially the same form. The submitting author has circulated the article and secured final approval of the version to be peer-reviewed from all coauthors prior to article submission.
This includes confirmation of absence of previous similar or simultaneous publications, their inspection of the manuscript, their substantial contribution to the work, and their agreement to submission.
Conflict of Interest Disclosures
F. Weidemann, J. Krämer, and C. Wanner have received speaker honoraria from Genzyme Corporation and Shire. F. Weidemann and C. Wanner are members of the Fabry Registry European Board of Advisors and have received travel assistance and speaker honoraria. The institution has received research grants from Genzyme Corporation and Shire.
Peter Nordbeck, Stefan Störk, Christian Ritter, and Georg Ertl declare that they have no conflict of interest.
Contributorship Statement
Johannes Krämer, first draft, concept of the manuscript, data interpretation, statistical analysis; Peter Nordbeck, interpretation of the data, concept manuscript, revision manuscript; Stefan Störk, statistical analysis, revision manuscript; Christian Ritter, magnetic resonance imaging, revision manuscript; Georg Ertl, revision manuscript, supervision; Christoph Wanner, interpretation of the data, revision manuscript; Frank Weidemann, interpretation of the data, concept manuscript, revision manuscript, supervision.
Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. This article does not contain any studies with human or animal subjects performed by the any of the authors.
Rights and permissions
Copyright information
© 2015 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Krämer, J. et al. (2015). Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy. In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 28. JIMD Reports, vol 28. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2015_502
Download citation
DOI: https://doi.org/10.1007/8904_2015_502
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-52846-4
Online ISBN: 978-3-662-52847-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)